BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lima JJ, Lang JE, Mougey EB, Blake KB, Gong Y, Holbrook JT, Wise RA, Teague WG. Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. J Pediatr 2013;163:686-91. [PMID: 23623526 DOI: 10.1016/j.jpeds.2013.03.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Stark CM, Nylund CM. Side Effects and Complications of Proton Pump Inhibitors: A Pediatric Perspective. The Journal of Pediatrics 2016;168:16-22. [DOI: 10.1016/j.jpeds.2015.08.064] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
2 Lang JE, Holbrook JT, Lima JJ; American Lung Association-Asthma Clinical Research Centers. Reply: worsening asthma control in children taking lansoprazole: possible mechanisms. Ann Am Thorac Soc 2015;12:1110-1. [PMID: 26203617 DOI: 10.1513/AnnalsATS.201505-298LE] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
3 Franciosi JP, Mougey EB, Williams A, Gomez Suarez RA, Thomas C, Creech CL, George K, Corao D, Lima JJ. Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment. Eur J Pediatr 2018;177:69-77. [PMID: 29209919 DOI: 10.1007/s00431-017-3051-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
4 Blandizzi C, Scarpignato C. Gastrointestinal Drugs. A worldwide yearly survey of new data in adverse drug reactions. Elsevier; 2014. pp. 539-60. [DOI: 10.1016/b978-0-444-63407-8.00036-8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14:447-460. [PMID: 29620484 DOI: 10.1080/17425255.2018.1461835] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
6 Rieder MJ, Carleton B. Pharmacogenomics and adverse drug reactions in children. Front Genet 2014;5:78. [PMID: 24795743 DOI: 10.3389/fgene.2014.00078] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
7 Lang JE, Holbrook JT, Mougey EB, Wei CY, Wise RA, Teague WG, Lima JJ; American Lung Association-Airways Clinical Research Centers. Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. Ann Am Thorac Soc 2015;12:878-85. [PMID: 25844821 DOI: 10.1513/AnnalsATS.201408-391OC] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
8 Mougey EB, Williams A, Coyne AJK, Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, Rayo A, Echeverría L, Román E, González Lois C, Chao M, Al-Atrash H, Lima JJ, Franciosi JP. CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr 2019;69:581-7. [PMID: 31490856 DOI: 10.1097/MPG.0000000000002480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
9 Aka I, Bernal CJ, Carroll R, Maxwell-Horn A, Oshikoya KA, Van Driest SL. Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. J Pers Med 2017;7:E14. [PMID: 29099060 DOI: 10.3390/jpm7040014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
10 Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DL, Scott SA, Schwab M, Uppugunduri CRS, Formea CM, Franciosi JP, Sangkuhl K, Gaedigk A, Klein TE, Gammal RS, Furuta T. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther 2021;109:1417-23. [PMID: 32770672 DOI: 10.1002/cpt.2015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
11 Cicali EJ, Blake K, Gong Y, Mougey EB, Al-Atrash H, Chambers N, Denham J, Evans J, George DE, Gomez R, Palomo P, Taufiq S, Johnson JA, Lima JJ, Franciosi JP. Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial. Clin Transl Sci 2019;12:172-9. [PMID: 30341969 DOI: 10.1111/cts.12589] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
12 Rosen R, Rahbar R. Proton Pump Inhibitor Use and Outcomes in Children With Respiratory Symptoms. JAMA Otolaryngol Head Neck Surg 2018;144:555. [DOI: 10.1001/jamaoto.2018.0466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Lima JJ, Franciosi JP. Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs. Pharmacogenomics 2014;15:1405-16. [PMID: 25303292 DOI: 10.2217/pgs.14.103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
14 Hait EJ, McDonald DR. Impact of Gastroesophageal Reflux Disease on Mucosal Immunity and Atopic Disorders. Clin Rev Allergy Immunol 2019;57:213-25. [PMID: 30206783 DOI: 10.1007/s12016-018-8701-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
15 Franciosi JP, Mougey EB, Dellon ES, Gutierrez-junquera C, Fernandez-fernandez S, Venkatesh RD, Gupta SK. Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions. JAA 2022;Volume 15:281-302. [DOI: 10.2147/jaa.s274524] [Reference Citation Analysis]
16 Gonzalez D, Paul IM, Benjamin DK Jr, Cohen-Wolkowiez M. Advances in pediatric pharmacology, therapeutics, and toxicology. Adv Pediatr 2014;61:7-31. [PMID: 25037123 DOI: 10.1016/j.yapd.2014.03.005] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Tang M, Henderson RJ, Holbrook JT, Que LG, Mathews AM, Wise RA, Dixon AE, Peters SP, Rogers L, Smith LJ, Teague WG, Lang JE. Does Obesity Increase Respiratory Tract Infections in Patients with Asthma? J Allergy Clin Immunol Pract 2019;7:954-961.e6. [PMID: 30312805 DOI: 10.1016/j.jaip.2018.09.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
18 Wiciński M, Malinowski B, Puk O, Górski K, Adamkiewicz D, Chojnacki G, Walczak M, Wódkiewicz E, Szambelan M, Adamska P, Skibińska K, Socha M, Słupski M, Pawlak-Osińska K. Possible Effects of Proton Pump Inhibitors on Hearing Loss Development. Biomed Res Int 2019;2019:4853695. [PMID: 31915695 DOI: 10.1155/2019/4853695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Sabet S, McGhee JE. New Guidance on Cytochrome P450 2C19 Phenotype-based Use of Proton Pump Inhibitors. J Pediatr Gastroenterol Nutr 2021;72:697-9. [PMID: 33720093 DOI: 10.1097/MPG.0000000000003082] [Reference Citation Analysis]
20 Tang Girdwood SC, Rossow KM, Van Driest SL, Ramsey LB. Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians. Pediatr Res 2021. [PMID: 33824446 DOI: 10.1038/s41390-021-01499-2] [Reference Citation Analysis]
21 Franciosi JP, Mougey EB, Williams A, Gomez-Suarez RA, Thomas C, Creech CL, George K, Corao D, Lima JJ. Association Between CYP2C19*17 Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal Reflux. J Clin Pharmacol 2018;58:89-96. [PMID: 28884817 DOI: 10.1002/jcph.977] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
22 Bernal CJ, Aka I, Carroll RJ, Coco JR, Lima JJ, Acra SA, Roden DM, Van Driest SL. CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections. Pediatrics 2019;144:e20190857. [PMID: 31699831 DOI: 10.1542/peds.2019-0857] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
23 Wang C, Li C, Hsieh R, Fan C, Hsu T, Chang W, Hsu W, Lin Y, Lee C. Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta‐analysis of randomized controlled trials and observational studies. Expert Opinion on Drug Safety 2019;18:163-72. [DOI: 10.1080/14740338.2019.1577820] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
24 Montes M, Villalon FN, Eizaguirre FJ, Delgado M, Muñoz-Seca IM, Fernández-Reyes M, Pérez-Trallero E. Helicobacter pylori Infection in Children. Antimicrobial Resistance and Treatment Response. Helicobacter 2015;20:169-75. [PMID: 25382231 DOI: 10.1111/hel.12187] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
25 Tang M, Blake KV, Lima JJ, Mougey EB, Franciosi J, Schmidt S, Hossain MJ, Cobbaert M, Fischer BM, Lang JE. Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods. Contemp Clin Trials 2019;78:27-33. [PMID: 30659924 DOI: 10.1016/j.cct.2019.01.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]